NCT07041840 ReModeling in ST-elevation myocARrdial Infarction: a Comparison of Left VEntricuLar Functions in Long-term Follow-up Among STEMI Patients
| NCT ID | NCT07041840 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pisa |
| Condition | STEMI |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2024-01-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients diagnosed with STEMI who underwent pPCI were included in this study. The investigators collected comprehensive data on each patient's status, including laboratory findings such as NT-proBNP, troponin levels, and inflammatory profile assessed by leukocyte count, C-reactive protein, interleukin-1, and interleukin-6. Additionally, electrocardiographic and echocardiographic features, details of the coronary intervention procedure, hospital stay duration, complications, and medical treatments were recorded. Comprehensive transthoracic echocardiograms (TTE) were performed at admission and before discharge. Myocardial tissue characterization was conducted by cardiac magnetic resonance (CMR) imaging before discharge, assessing intramyocardial hemorrhage (IMH), microvascular obstruction (MVO), infarct size (IS), area at risk (AAR), salvaged myocardium, and salvage index. At the six-month follow-up, laboratory tests, CMR imaging, and TTE were repeated, along with a thorough clinical evaluation. LVR was defined by one of the following criteria: a 20% increase in end-diastolic volume by TTE or 12% by CMR, a 15% increase in end-systolic volume, a sphericity index greater than 42% (CMR only), the emergence of new concentric hypertrophy, or a reduction greater than 10% in left ventricular ejection fraction (LVEF).
Eligibility Criteria
Inclusion Criteria: * STEMI Exclusion Criteria: * Contraindication to CMR imaging
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07041840 clinical trial?
This trial is open to participants of all sexes, studying STEMI. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07041840 currently recruiting?
Yes, NCT07041840 is actively recruiting participants. Contact the research team at mattia.alberti96@outlook.it for enrollment information.
Where is the NCT07041840 trial being conducted?
This trial is being conducted at Pisa, Italy.
Who is sponsoring the NCT07041840 clinical trial?
NCT07041840 is sponsored by University of Pisa. The trial plans to enroll 80 participants.